AgingResearch.NewsJoin free

Solid Biosciences

CompanyUnited States

Solid Biosciences develops 4 assets, the furthest in clinical trials with no phase (SGT-001 in Duchenne muscular dystrophy). Mostly gene therapy acting on DMD, FXN and BAG3; based in the United States.

4
Assets
Furthest stage
Clinical, no phase
Raised
$159M
0
Trials
1
Signal

Pipeline

4

  • SGT-001

    Delivers a microdystrophin gene to restore muscle dystrophin function and support neuronal nitric oxide synthase activity.

    Clinical, no phase, Gene therapy, DMD, Duchenne muscular dystrophy

  • AVB-202

    Delivers a functional frataxin gene using an AAV vector to restore mitochondrial frataxin expression.

    Preclinical, Gene therapy, FXN, Friedreich ataxia

  • AVB-401

    Delivers a functional BAG3 gene to restore BAG3 expression in cardiac muscle.

    Preclinical, Gene therapy, BAG3, BAG3-mediated dilated cardiomyopathy

1 more asset

Full company profiles: pipeline, trials, funding and people.

See Pro

Subsidiaries

1

In the full profile

  • Evidence behind the mechanisms3
  • Funding rounds and grants4
  • Deals9
  • Signals2
  • Similar companies6

Intelligence